The Risk of Venous Thromboembolism (VTE) in Men with Benign Prostatic Hyperplasia Treated with 5-Alpha Reductase Inhibitors (5ARIs).

References

• Naslund MJ, Gilsenan AW, Midkiff KD, Bown A, Wolford ET, Wang J. Prevalence of lower urinary tract symptoms and prostate enlargement in the primary care setting. Int J Clin Pract. 2007;61(9):1437–1445. doi:10.1111/j.1742-1241.2007.01508.x17686091
   PubMed Web of Science ®Google Scholar
• Emberton M, Marberger M, De La Rosette J. Understanding patient and physician perceptions of benign prostatic hyperplasia in Europe: the prostate research on behaviour and education (PROBE) survey. Int J Clin Pract. 2008;62:18. doi:10.1111/j.1742-1241.2007.01635.x18028388
   PubMed Web of Science ®Google Scholar
• Emberton M, Fitzpatrick JM, Rees J. Risk stratification for benign prostatic hyperplasia (BPH) treatment. BJU Int. 2011;107:876–880. doi:10.1111/j.1464-410X.2010.10041.x21265993
   PubMed Web of Science ®Google Scholar
• Saylor PJ, Smith MR. Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol. 2009;181(5):1998–2008. doi:10.1016/j.juro.2009.01.04719286225
   PubMed Web of Science ®Google Scholar
• Keating NL, O’Malley AJ, Freedland SJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst. 2010;102(1):39–46. doi:10.1093/jnci/djp40419996060
   PubMed Web of Science ®Google Scholar
• Jespersen CG, Nørgaard M, Borre M. Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study. Eur Urol. 2014;65(4):704–709. doi:10.1016/j.eururo.2013.02.00223433805
   PubMed Web of Science ®Google Scholar
• Araujo AB, Kupelian V, Page ST, Handelsman DJ, Bremner WJ, McKinlay JB. Sex steroids and all-cause and cause-specific mortality in men. Arch Intern Med. 2007;167:1252. doi:10.1001/archinte.167.12.125217592098
   PubMed Web of Science ®Google Scholar
• Walker RF, Zakai NA, Maclehose RF, et al. Association of testosterone therapy with risk of venous thromboembolism among men with and without hypogonadism. JAMA Intern Med. 2020;180(2):190–197. doi:10.1001/jamainternmed.2019.513531710339
   PubMed Web of Science ®Google Scholar
• Yao S, Till C, Kristal AR, et al. Serum estrogen levels and prostate cancer risk in the prostate cancer prevention trial: a nested case-control study. Cancer Causes Control. 2011;22:1121–1131. doi:10.1007/s10552-011-9787-721667068
   PubMed Web of Science ®Google Scholar
• Simon T, De Jonage-canonico MBY, Oger E, et al. Indicators of lifetime endogenous estrogen exposure and risk of venous thromboembolism. J Thromb Haemost. 2006;4:71–76. doi:10.1111/j.1538-7836.2005.01693.x16409454
   PubMed Web of Science ®Google Scholar
• Choi BK, Cheon K, Cho B-H, Jung JW, Yl K. Cerebral venous sinus thrombosis associated with dutasteride use. Yonsei Med J. 2020;61(6):553–555. doi:10.3349/ymj.2020.61.6.55332469180
   PubMed Web of Science ®Google Scholar
• Kang DW, Jeong HG, Kim HR, et al. Finasteride induced cerebral venous thrombosis. J Korean Neurol Assoc. 2015;33:238–240. doi:10.17340/jkna.2015.3.22
   Google Scholar
• Mansouri P, Farshi S, Safar F. Finasteride-induced gynecomastia. Indian J Dermatol Venereol Leprol. 2009;75:309–310. doi:10.4103/0378-6323.5127319439893
   PubMed Web of Science ®Google Scholar
• Ferrando J. Unilateral gynecomastia induced by treatment with 1 mg of oral finasteride. Arch Dermatol. 2004. doi:10.1001/archderm.138.4.543
   Google Scholar
• Green L, Wysowski DK, Fourcroy JL. Gynecomastia and breast cancer during finasteride therapy. N Engl J Med. 2002;138:543. doi:10.1056/nejm199609123351116
   Web of Science ®Google Scholar
• Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology. 2002;60(3):434–441. doi:10.1016/S0090-4295(02)01905-212350480
   PubMed Web of Science ®Google Scholar
• Desgrandchamps F, Droupy S, Irani J, Saussine C, Comenducci A. Effect of dutasteride on the symptoms of benign prostatic hyperplasia, and patient quality of life and discomfort, in clinical practice. BJU Int. 2006;98(1):83–88. doi:10.1111/j.1464-410X.2006.06241.x16831149
   PubMed Web of Science ®Google Scholar
• Debruyne F, Barkin J, Van EP, Reis M, Tammela TLJ, Roehrborn C. Efficacy and safety of long-term treatment with the dual 5α-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol. 2004;46(4):488–495. doi:10.1016/j.eururo.2004.05.00815363566
   PubMed Web of Science ®Google Scholar
• Gormley GJ, Stoner E, Bruskewitz RC, et al. The effect of finasteride in men with benign prostatic hyperplasia. 1992. J Urol. 2002;167(2 Pt 2):1102–1107. doi:10.1016/s0022-5347(02)80349-411905882
   PubMed Web of Science ®Google Scholar
• Andriole GL, Kirby R. Safety and tolerability of the dual 5α-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia. Eur Urol. 2003;44(1):82–88. doi:10.1016/S0302-2838(03)00198-212814679
   PubMed Web of Science ®Google Scholar
• Gregson J, Kaptoge S, Bolton T, et al. Cardiovascular risk factors associated with venous thromboembolism. JAMA Cardiol. 2019;4(2):163. doi:10.1001/jamacardio.2018.453730649175
   PubMed Web of Science ®Google Scholar
• Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349(3):215–224. doi:10.1056/nejmoa03066012824459
   PubMed Web of Science ®Google Scholar
• Miller JA, Pramanik B, Gilhooly P. Waxing and waning gynecomastia: an indication of noncompliant use of prescribed medication. South Med J. 1999;92(6):615–617. doi:10.1097/00007611-199906000-0001210372857
   PubMed Web of Science ®Google Scholar
• Olsen EA, Hordinsky M, Whiting D, et al. The importance of dual 5α-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol. 2006;55(6):1014–1023. doi:10.1016/j.jaad.2006.05.00717110217
   PubMed Web of Science ®Google Scholar
• Grino P, Stoner E, Andriole GL, et al. Finasteride for the treatment and control of benign prostatic hyperplasia: summary of Phase III controlled studies. Eur Urol. 1994;25(SUPPL. 1):24–28. doi:10.1159/0004753287507052
   PubMed Web of Science ®Google Scholar
• Traish AM, Hassani J, Guay AT, Zitzmann M, Hansen ML. Adverse side effects of 5α-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients. J Sex Med. 2011;8(3):872–884. doi:10.1111/j.1743-6109.2010.02157.x21176115
   PubMed Web of Science ®Google Scholar
• Shenoy NK, Prabhakar SM. Finasteride and male breast cancer: does the MHRA report show a link? J Cutan Aesthet Surg. 2010;3(2):102–105. doi:10.4103/0974-2077.6902221031070
   PubMedGoogle Scholar
• Tsuji Y, Nakayama T, Bono K, Kitamura M, Imafuku I. Two cases of stroke associated with the use of finasteride, an approved drug for male-pattern hair loss in Japan. Rinsho Shinkeigaku. 2014;54:423–428. doi:10.5692/clinicalneurol.54.42324943080
   PubMedGoogle Scholar
• Sacco S, Ricci S, Degan D, Carolei A. Migraine in women: the role of hormones and their impact on vascular diseases. J Headache Pain. 2012;13(3):177–189. doi:10.1007/s10194-012-0424-y22367631
   PubMed Web of Science ®Google Scholar
• Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Female hormones and thrombosis. Arterioscler Thromb Vasc Biol. 2002;22(2):201–210. doi:10.1161/hq0202.10231811834517
   PubMed Web of Science ®Google Scholar
• Parkin L, Sharples K, Hernandez RK, Jick SS. Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK general practice research database. BMJ. 2011;342(apr21 2):d2139–d2139. doi:10.1136/bmj.d213921511804
   PubMed Web of Science ®Google Scholar
• Malkin CJ, Pugh PJ, Jones RD, Jones TH, Channer KS. Testosterone as a protective factor against atherosclerosis - immunomodulation and influence upon plaque development and stability. J Endocrinol. 2003;178:373–380. doi:10.1677/joe.0.178037312967330
   PubMed Web of Science ®Google Scholar
• García Rodríguez LA, Pérez Gutthann S. Use of the UK general practice research database for pharmacoepidemiology. Br J Clin Pharmacol. 1998;45(5):419–425. doi:10.1046/j.1365-2125.1998.00701.x9643612
   PubMed Web of Science ®Google Scholar
• Lawrenson R, Todd JC, Leydon GM, Williams TJ, Farmer RDT. Validation of the diagnosis of venous thromboembolism in general practice database studies. Br J Clin Pharmacol. 2000;49:591–596. doi:10.1046/j.1365-2125.2000.00199.x10848723
   PubMed Web of Science ®Google Scholar
• Huerta C, Johansson S, Wallander MA, García Rodríguez LA. Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Arch Intern Med. 2007;167:935. doi:10.1001/archinte.167.9.93517502535
   PubMedGoogle Scholar
• Charlson ME, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47(11):1245–1251. doi:10.1016/0895-4356(94)90129-5
   Google Scholar
• Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–383. doi:10.1016/0021-9681(87)90171-83558716
   PubMedGoogle Scholar
• Ording AG, Horváth-Puhõ E, Lash TL, et al. Prostate cancer, comorbidity, and the risk of venous thromboembolism: a cohort study of 44,035 Danish prostate cancer patients,1995–2011.Cancer.2015;121(20):3692–3699. doi:10.1002/cncr.2953526149752
   PubMed Web of Science ®Google Scholar
• Baillargeon J, Urban RJ, Morgentaler A, et al. Risk of venous thromboembolism in men receiving testosterone therapy. Mayo Clin Proc. 2015;90:1038–1045. doi:10.1016/j.mayocp.2015.05.01226205547
   PubMed Web of Science ®Google Scholar
• Swerdloff RS, Dudley RE, Page ST, Wang C, Salameh WA. Dihydrotestosterone: biochemistry, physiology, and clinical implications of elevated blood levels. Endocr Rev. 2017;38:220. doi:10.1210/er.2016-106728472278
   PubMed Web of Science ®Google Scholar
• Nishiyama T, Hashimoto Y, Takahashi K. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer. Clin Cancer Res. 2004;10(21):7121–7126. doi:10.1158/1078-0432.CCR-04-091315534082
   PubMed Web of Science ®Google Scholar
• Chang J, Choi S, Kim K, Park SM. Cardiovascular Safety and Possible Benefit of a 5-Alpha Reductase Inhibitor among Benign Prostatic Hyperplasia Patients, A Nationally Representative Cohort of Korean Men. J Clin Med. 2019;8(5):733. doi:10.3390/jcm8050733
   Google Scholar
• Yeap BB, Alfonso H, Paul Chubb SA, et al. In older men an optimal plasma testosterone is associated with reduced all-cause mortality and higher dihydrotestosterone with reduced ischemic heart disease mortality, while estradiol levels do not predict mortality. J Clin Endocrinol Metab. 2014;99(1):E9–E18. doi:10.1210/jc.2013-327224257908
   PubMed Web of Science ®Google Scholar
• Azzouni F, Godoy A, Li Y, Mohler J. The 5 alpha-reductase isozyme family: a review of basic biology and their role in human diseases. Adv Urol. 2012;2012:1–18. doi:10.1155/2012/530121
   Google Scholar
• Roehrborn CG, Marks LS, Fenter T, et al. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Urology. 2004;63(4):709–715. doi:10.1016/j.urology.2004.01.00115072886
   PubMed Web of Science ®Google Scholar
• Trost L, Saitz TR, Hellstrom WJ. Side effects of 5‐alpha reductase inhibitors: a comprehensive review. Sex Med Rev. 2013;1:24‐41. doi:10.1002/smrj.3
   Google Scholar
• Shores MM, Biggs ML, Arnold AM, et al. Testosterone, dihydrotestosterone, and incident cardiovascular disease and mortality in the cardiovascular health study. J Clin Endocrinol Metab. 2014;99(6):2061–2068. doi:10.1210/jc.2013-357624628549
   PubMed Web of Science ®Google Scholar
• Loke YK, Ho R, Smith M, et al. Systematic review evaluating cardiovascular events of the 5-alpha reductase inhibitor - Dutasteride. J Clin Pharm Ther. 2013;38(5):405–415. doi:10.1111/jcpt.1208023815285
   PubMed Web of Science ®Google Scholar
• Hsieh TF, Yang YW, Sen LS, et al. Use of 5-alpha-reductase inhibitors did not increase the risk of cardiovascular diseases in patients with benign prostate hyperplasia: a five-year follow-up study. PLoS One. 2015;10:e0119694. doi:10.1371/journal.pone.011969425803433
   PubMed Web of Science ®Google Scholar
• Klotz L, Nabid A, Higano C, Ryan C, Kebabdjian M, Chin J. Effect of dutasteride in men receiving intermittent androgen ablation therapy: the AVIAS trial. J Can Urol Assoc. 2014;8(11–12):789. doi:10.5489/cuaj.2332
   Web of Science ®Google Scholar
• Ghanadian R, Lewis JG, Chisolm GD, O’Donoghue EPN. Serum dihydrotestosterone in patients with benign prostatic hypertrophy. Br J Urol. 1977;49:541–544. doi:10.1111/j.1464-410X.1977.tb04202.x73397
   PubMedGoogle Scholar
• Horton R, Hsieh P, Barberia J, Pages L, Cosgrove M. Altered blood androgens in elderly men with prostate hyperplasia. J Clin Endocrinol Metab. 1975;41:793–796. doi:10.1210/jcem-41-4-7931176586
   PubMed Web of Science ®Google Scholar
• Uygur MC, Arik AI, Altuǧ U, Erol D. Effects of the 5α-reductase inhibitor finasteride on serum levels of gonadal, adrenal, and hypophyseal hormones and its clinical significance: a prospective clinical study. Steroids. 1998;63:208–213. doi:10.1016/S0039-128X(98)00005-19589555
   PubMed Web of Science ®Google Scholar